Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
for source : Www.alnylam.com save search
New Long-Term Results for GIVLAARI® (givosiran) Presented at ASH Annual Meeting & Exposition
Published: 2021-12-13 (Crawled : 00:00) - alnylam.com
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
|
| O: 6.02%
H: 2.03%
C: -0.29%
givlaari results
New Results for Zilebesiran Presented at AHA Scientific Sessions 2021
Published: 2021-11-13 (Crawled : 16:20) - alnylam.com
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
| Email alert
Add to watchlist
results
New Long-Term Results for GIVLAARI® (givosiran) Presented at UEG Week Virtual 2021
Published: 2021-10-04 (Crawled : 13:00) - alnylam.com
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
|
| O: 3.34%
H: 1.56%
C: 0.01%
results
New Results for Vutrisiran at EU-ATTR Amyloidosis Meeting
Published: 2021-09-07 (Crawled : 14:00) - alnylam.com
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
|
| O: -0.93%
H: 0.0%
C: -4.76%
results
RNAi Roundtable: Lumasiran, for the Treatment of Primary Hyperoxaluria Type 1
Published: 2021-08-19 (Crawled : 14:00) - alnylam.com
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
|
| O: -0.55%
H: 2.32%
C: 0.28%
treatment
RNAi Roundtable: Givosiran, for the Treatment of Acute Hepatic Porphyria
Published: 2021-08-04 (Crawled : 18:00) - alnylam.com
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
|
| O: -0.88%
H: 5.21%
C: 3.5%
treatment hepatitis
RNAi Roundtable: Patisiran & Vutrisiran, in Development for the Treatment of Transthyretin-Mediated Amyloidosis
Published: 2021-07-16 (Crawled : 15:00) - alnylam.com
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
|
| O: 0.62%
H: 2.86%
C: 2.61%
media treatment
RNAi Roundtable: Zilebesiran (ALN-AGT), in Development for the Treatment of Hypertension
Published: 2021-06-30 (Crawled : 15:00) - alnylam.com
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
|
| O: -0.28%
H: 5.14%
C: 2.48%
treatment hypertension
Early Results on Clinical Outcome Measures Presented for OXLUMO® (lumasiran) at ASPN/PAS 2021 Annual Congress
Published: 2021-05-03 (Crawled : 12:00) - alnylam.com
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
|
| O: -0.11%
H: 0.09%
C: -3.66%
tcom results
HELIOS-A Phase 3 Results for Vutrisiran Presented at AAN
Published: 2021-04-19 (Crawled : 19:00) - alnylam.com
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
|
| O: -4.11%
H: 3.92%
C: 3.25%
results phase 3 presentation
New Results for ALN-AGT at the ESH-ISH 2021 Joint Meeting
Published: 2021-04-11 (Crawled : 16:20) - alnylam.com
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
| Email alert
Add to watchlist
results
ILLUMINATE-A Phase 3 Results for Lumasiran Published in The New England Journal of Medicine
Published: 2021-03-31 (Crawled : 22:00) - alnylam.com
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
|
| O: 1.4%
H: 1.39%
C: -0.95%
results phase 3
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.